Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06045793 · ClinicalTrials.gov registry record · Phase 2
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
A Phase 2 study, sponsored by Tonix Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06045793: Clinical Trial Phase 2 study, sponsored by Tonix Pharmaceuticals.
NCT06045793 is a Phase 2 study that was terminated before completion, run by Tonix Pharmaceuticals. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06045793, a Phase 2 study, was terminated before completion, sponsored by Tonix Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.
Primary Outcome
Patients will undergo a Systolic BP assessment at Baseline and at 60 minutes after dosing.
Interventions
- DRUG TNX-1300 (Injection)
- DRUG Placebo (Injection)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2025-04-21 |
| Phase | Phase 2 |
Why NCT06045793 stopped before completion
NCT06045793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which TNX-1300 (Injection) is the first listed.
NCT06045793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06045793 about?
NCT06045793 is a clinical study titled "Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)". This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.
What is the current status of trial NCT06045793?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2024-08-16. Estimated completion is 2025-04-21.
What interventions are being tested in trial NCT06045793?
The interventions under investigation include: TNX-1300 (Injection) (DRUG), Placebo (Injection) (DRUG).
Who is sponsoring clinical trial NCT06045793?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06045793's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI